MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 466154 | Name: Sotradecol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sotradecol is a Sclerosing (skler-OH-sing) agent, showing efficacy in the treatment of varicose veins, telangiectasias, hemangioma, pyogenic granuloma, cherry angioma, Kaposi sarcoma, lymphangioma circumscriptum, digital mucous cyst, ganglion cyst, glomangioma, angiokeratoma of Fordyce, pseudocyst of the auricle, and verruca.

Chemical Structure

Sotradecol
Sotradecol
CAS#139-88-8

Theoretical Analysis

MedKoo Cat#: 466154

Name: Sotradecol

CAS#: 139-88-8

Chemical Formula: C14H29NaO4S

Exact Mass: 316.1684

Molecular Weight: 316.43

Elemental Analysis: C, 53.14; H, 9.24; Na, 7.27; O, 20.22; S, 10.13

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Sotradecol; Sodium tetradecyl sulfate; Trombovar;
IUPAC/Chemical Name
sodium 7-ethyl-2-methylundecan-4-yl sulfate
InChi Key
FVEFRICMTUKAML-UHFFFAOYSA-M
InChi Code
InChI=1S/C14H30O4S.Na/c1-5-7-8-13(6-2)9-10-14(11-12(3)4)18-19(15,16)17;/h12-14H,5-11H2,1-4H3,(H,15,16,17);/q;+1/p-1
SMILES Code
O=S(OC(CCC(CC)CCCC)CC(C)C)([O-])=O.[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 316.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: de Ávila Oliveira R, Riera R, Vasconcelos V, Baptista-Silva JC. Injection sclerotherapy for varicose veins. Cochrane Database Syst Rev. 2021 Dec 10;12(12):CD001732. doi: 10.1002/14651858.CD001732.pub3. PMID: 34883526; PMCID: PMC8660237. 2: Nakano LC, Cacione DG, Baptista-Silva JC, Flumignan RL. Treatment for telangiectasias and reticular veins. Cochrane Database Syst Rev. 2021 Oct 12;10(10):CD012723. doi: 10.1002/14651858.CD012723.pub2. PMID: 34637138; PMCID: PMC8507602. 3: Sotiris D, Pallotta G, Nittari G, Amenta F. An Original Approach for the Treatment of Varicose Veins of the Lower Limbs. J Clin Aesthet Dermatol. 2020 Aug;13(8):E59-E64. Epub 2020 Aug 1. PMID: 33178385; PMCID: PMC7595361. 4: De Maria L, De Sanctis P, Balakrishnan K, Tollefson M, Brinjikji W. Sclerotherapy for Venous Malformations of Head and Neck: Systematic Review and Meta-Analysis. Neurointervention. 2020 Mar;15(1):4-17. doi: 10.5469/neuroint.2019.00213. Epub 2020 Jan 16. PMID: 31940716; PMCID: PMC7105094. 5: Legiehn GM. Sclerotherapy with Adjunctive Stasis of Efflux (STASE) in Venous Malformations: Techniques and Strategies. Tech Vasc Interv Radiol. 2019 Dec;22(4):100630. doi: 10.1016/j.tvir.2019.100630. Epub 2019 Sep 21. PMID: 31864535. 6: Stuepp RT, Scotti FM, Melo G, Munhoz EA, Modolo F. Effects of sclerosing agents on head and neck hemangiomas: A systematic review. J Clin Exp Dent. 2019 Nov 1;11(11):e1033-e1044. doi: 10.4317/jced.56143. PMID: 31700578; PMCID: PMC6825735. 7: Bai T, Liu Y, Jiang W, Li Y, Liu J, Yu C, Fan Y. A Review of Sclerosing Foam Stability in the Treatment of Varicose Veins. Dermatol Surg. 2020 Feb;46(2):249-257. doi: 10.1097/DSS.0000000000002039. PMID: 31569112. 8: Lam SC, Yuen HKL. Medical and sclerosing agents in the treatment of orbital lymphatic malformations: what's new? Curr Opin Ophthalmol. 2019 Sep;30(5):380-385. doi: 10.1097/ICU.0000000000000585. PMID: 31232717. 9: Abbasi N, Morency AM, Langer JC, Chiu PPL, Chami R, Windrim R, Keunen J, Seaward G, Ryan G. Fetal Sclerotherapy for Hydropic Congenital Cystic Adenomatoid Malformations of the Lung Refractory to Steroids: A Case Report and Review of the Literature. Fetal Diagn Ther. 2020;47(1):24-33. doi: 10.1159/000497143. Epub 2019 May 21. PMID: 31112955. 10: Kobayakawa M, Ohnishi S, Suzuki H. Recent development of balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol. 2019 Mar;34(3):495-500. doi: 10.1111/jgh.14463. Epub 2018 Sep 17. PMID: 30170340. 11: Taylor WSJ, Cobley J, Mahmalji W. Is aspiration and sclerotherapy treatment for hydroceles in the aging male an evidence-based treatment? Aging Male. 2019 Sep;22(3):163-168. doi: 10.1080/13685538.2018.1425987. Epub 2018 Jan 16. PMID: 29336195. 12: Facciolà A, Venanzi Rullo E, Ceccarelli M, D'Aleo F, Di Rosa M, Pinzone MR, Condorelli F, Visalli G, Picerno I, Fisichella R, Nunnari G, Pellicanò GF. Kaposi's sarcoma in HIV-infected patients in the era of new antiretrovirals. Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5868-5869. doi: 10.26355/eurrev_201712_14036. PMID: 29272026. 13: Jenkinson HA, Wilmas KM, Silapunt S. Sodium Tetradecyl Sulfate: A Review of Clinical Uses. Dermatol Surg. 2017 Nov;43(11):1313-1320. doi: 10.1097/DSS.0000000000001143. PMID: 28430735. 14: Patel KC, Kalantzis G, El-Hindy N, Chang BY. Sclerotherapy for Orbital Lymphangioma - Case Series and Literature Review. In Vivo. 2017 Mar- Apr;31(2):263-266. doi: 10.21873/invivo.11055. PMID: 28358710; PMCID: PMC5411755. 15: Sio WS, Lee SH, Liang IC. Orbital infarction syndrome after multiple percutaneous sclerotherapy sessions for facial low-flow vascular malformation: A case report and literature review. Indian J Ophthalmol. 2016 Aug;64(8):595-7. doi: 10.4103/0301-4738.191508. PMID: 27688283; PMCID: PMC5056549. 16: Horbach SE, Lokhorst MM, Saeed P, de Goüyon Matignon de Pontouraude CM, Rothová A, van der Horst CM. Sclerotherapy for low-flow vascular malformations of the head and neck: A systematic review of sclerosing agents. J Plast Reconstr Aesthet Surg. 2016 Mar;69(3):295-304. doi: 10.1016/j.bjps.2015.10.045. Epub 2015 Nov 18. PMID: 26723834. 17: Kuliński S, Gutkowska O, Gosk J. Chemical Substances Used in the Treatment of Ganglions Located in the Hand and Wrist. Polim Med. 2016 Jan- Jun;46(1):95-100. doi: 10.17219/pim/64803. PMID: 28397424. 18: Alder G, Lees T. Foam sclerotherapy. Phlebology. 2015 Nov;30(2 Suppl):18-23. doi: 10.1177/0268355515589536. PMID: 26556698. 19: Witte ME, Reijnen MM, de Vries JP, Zeebregts CJ. Mechanochemical Endovenous Occlusion of Varicose Veins Using the ClariVein® Device. Surg Technol Int. 2015 May;26:219-25. PMID: 26055013. 20: Kovacević J. Europske smjernice za skleroterapiju kod kronicnih venskih poremećaja [European guidelines for sclerotherapy in chronic venous disorders]. Acta Med Croatica. 2014 Oct;68 Suppl 1:127-44. Croatian. PMID: 25327003